ESMO 2018 | The PAOLA-1 study: olaparib and bevacizumab for ovarian cancer

In this video, Kathleen Moore, MD, principle investigator, from the Stephenson Cancer Center, Oklahoma City, OK, talks about the implications of the SOLO-1 trial (NCT01844986) and the necessity for earlier screening of BRCA in order to guide therapy. Dr Moore focuses on the PAOLA-1 trial (NCT02477644) that looks at olaparib combined with bevacizumab for patients with ovarian cancer without having to select for BRCA mutation, which could potentially result in increased accessibility to PARP inhibitors and bevacizumab. Dr Moore was speaking from the European Society for Medical Oncology (ESMO) 2018 Congress in Munich, Germany.